Please assess the completion status of the following clinical trial:

Trial Title: Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* For Groups A and B~  * Subjects for whom the investigator believes that parents/guardians can and will comply with the requirements of the protocol.~ * Healthy male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.~ * Written informed consent obtained from the parent or guardian of the subject.~ * Free of obvious health problems as established by medical history and clinical examination before entering the study.~ * Born after a gestation period between 36 and 42 weeks.~ * Infants who have not received a previous dose of hepatitis B vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrollment.~* For Group C~  * Subjects for whom the investigator believes that parents/guardians can and will comply with the requirements of the protocol.~ * Healthy male or female between, and including, 3 and 5 years of age at the time of the first vaccination.~ * Written informed consent obtained from the parent or guardian of the subject.~ * Free of obvious health problems as established by medical history and clinical examination before entering the study.~Exclusion Criteria:~-For Groups A and B~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine(s).~* Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliovirus, and/or Streptococcus pneumoniae; more than one previous dose of hepatitis B vaccine.~* History of Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, hepatitis B, poliovirus, and/or Streptococcus pneumoniae disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including dry natural latex rubber.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at time of enrollment.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~For Group C~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the dose of study vaccine.~* Previous vaccination against Neisseria meningitidis.~* History of Neisseria meningitidis disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, including dry natural latex rubber~* Major congenital defects or serious chronic illness.~* Acute disease at time of enrollment.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding vaccination or planned administration during the study period.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- MenHibrix Group (Type: EXPERIMENTAL): Subjects in the Group were followed during the entire study period, from Day 0 up to study end 6 months post fourth dose vaccinationDuring Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of Menhibrix™ co-administered with Pediarix™ and Prevnar™ (at Day 0 and Months 2 and 4). During Fourth-Dose Phase (Study 102015), subjects primed with 3 doses of Menhibrix™ during the Primary Phase received one dose of Menhibrix™ and one concomitant dose of Prevnar™ at Month 10-13. During Primary Phase, Menhibrix™ was administered intramuscularly (IM) in the right upper thigh, and Pediarix™ and Prevnar™ IM in the left upper and lower thighs, respectively. During Fourth-Dose Phase, Menhibrix™ was administered by the same route and at the same site as during Primary Phase, and Prevnar™ was administered IM in the left upper thigh.
- ActHIB Group (Type: ACTIVE_COMPARATOR): During Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of ActHIB™ vaccine co-administered with the Pediarix™ and Prevnar™ vaccines (at Day 0 and Months 2 and 4). Subjects in this Group were followed from Day 0 up to Month 10-13 solely. During Fourth-Dose Phase (Study 102015), these subjects were followed as subjects either in the ActHIB/MenHibrix Group or in the ActHIB/ActHIB Group, receiving then one dose of either Menhibrix™ or ActHIB™ concomitantly with one dose of Prevnar™. During Primary Phase, ActHIB™ was administered intramuscularly (IM) in the right upper thigh, and the Pediarix™ and Prevnar™ vaccines IM in the left upper and lower thighs, respectively.
- Menomune Group (Type: ACTIVE_COMPARATOR): Subjects in the Group were followed solely during the period of Primary Phase (Study 101858), up to Month 10. Subjects in the Group, aged 3-5 years at enrolment, received one dose of Menomune™ at Day 0. Menomune™ was administered subcutaneously in the left deltoid region.
- ActHIB/Menhibrix Group (Type: EXPERIMENTAL): Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase (study 101858) and received at Month 10-13 a fourth dose of Menhibrix™ and a concomitant fourth dose of Prevnar™. Menhibrix™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
- ActHIB/ActHIB Group (Type: EXPERIMENTAL): Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase of the study (study 101858) and received at Month 10-13 a fourth dose of ActHIB™ and a concomitant fourth dose of Prevnar™. ActHIB™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete